Evidence map›Paper›PMID 33348690›Full record

ReviewPharmaceutics2020

Supramolecular and Macromolecular Matrix Nanocarriers for Drug Delivery in Inflammation-Associated Skin Diseases.

Ranime Jebbawi, Séverine Fruchon, Cédric-Olivier Turrin, Muriel Blanzat, Rémy Poupot

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ranime JebbawiINSERM, U1043, CNRS, U5282, UPS, Centre de Physiopathologie de Toulouse-Purpan, Université de Toulouse, F-31300 Toulouse, France.ORCID 0000-0003-2058-8254
Séverine FruchonINSERM, U1043, CNRS, U5282, UPS, Centre de Physiopathologie de Toulouse-Purpan, Université de Toulouse, F-31300 Toulouse, France.ORCID 0000-0001-9382-0689
Cédric-Olivier TurrinCNRS, UPR 8241, Laboratoire de Chimie de Coordination, 205 Route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France.
Muriel BlanzatCNRS, UMR 5623, UPS, Laboratoire des Interactions Moléculaires et Réactivité Chimique et Photochimique, IMRCP, 118 Route de Narbonne, Université de Toulouse, CEDEX 9, F-31062 Toulouse, France.ORCID 0000-0002-5286-448X
Rémy PoupotINSERM, U1043, CNRS, U5282, UPS, Centre de Physiopathologie de Toulouse-Purpan, Université de Toulouse, F-31300 Toulouse, France.ORCID 0000-0003-1396-8531
Centre National de la Recherche Scientifique · FR

Funding

Agence Nationale de la Recherche ANR-18-CE18-0011Région Occitanie D-SKIN, # 2019-0019011695
6 · The paper itself

Abstract

Skin is our biggest organ. It interfaces our body with its environment. It is an efficient barrier to control the loss of water, the regulation of temperature, and infections by skin-resident and environmental pathogens. The barrier function of the skin is played by the stratum corneum (SC). It is a lipid barrier associating corneocytes (the terminally differentiated keratinocytes) and multilamellar lipid bilayers. This intricate association constitutes a very cohesive system, fully adapted to its role. One consequence of this efficient organization is the virtual impossibility for active pharmaceutical ingredients (API) to cross the SC to reach the inner layers of the skin after topical deposition. There are several ways to help a drug to cross the SC. Physical methods and chemical enhancers of permeation are a possibility. These are invasive and irritating methods. Vectorization of the drugs through nanocarriers is another way to circumvent the SC. This mini-review focuses on supramolecular and macromolecular matrices designed and implemented for skin permeation, excluding vesicular nanocarriers. Examples highlight the entrapment of anti-inflammatory API to treat inflammatory disorders of the skin.

Indexed as

atopic dermatitisdendrimerdermal deliverydrug deliverynanocarrierpsoriasisskin inflammation

Identifiers

PMID33348690
PMCPMC7766653
OpenAlexW3111250923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.